Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
Taiho Oncology, Inc.
University Health Network, Toronto
Brigham and Women's Hospital
Fred Hutchinson Cancer Center
Adela, Inc
OncoNano Medicine, Inc.
University Health Network, Toronto
Immunitas Therapeutics
Washington University School of Medicine
ModernaTX, Inc.
Incyte Corporation
University of Exeter
Rigshospitalet, Denmark
Tempus AI
Celgene
RenJi Hospital
Intensity Therapeutics, Inc.
Cedars-Sinai Medical Center
Cedars-Sinai Medical Center
Assistance Publique Hopitaux De Marseille
National Cancer Institute (NCI)
University Health Network, Toronto
RAPT Therapeutics, Inc.
Massachusetts General Hospital
University of Modena and Reggio Emilia
VitaMed Research LLC
University of Exeter
Cedars-Sinai Medical Center
Sanguine Biosciences
Presage Biosciences
Eisai Inc.
Icahn School of Medicine at Mount Sinai
Rutgers, The State University of New Jersey
Fate Therapeutics
Eastern Cooperative Oncology Group
Atara Biotherapeutics
Seagen Inc.
Fate Therapeutics
Genzada Pharmaceuticals USA, Inc.
Blue Note Therapeutics
Presage Biosciences
Incyte Corporation
Celgene
University College, London
Institut Bergonié
Celgene
Case Comprehensive Cancer Center
Tocagen Inc.